Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 13 (10), E317-E324

The Evolution of Percutaneous Nephrolithotomy: Analysis of a Single Institution Experience Over 25 Years


The Evolution of Percutaneous Nephrolithotomy: Analysis of a Single Institution Experience Over 25 Years

Jennifer Bjazevic et al. Can Urol Assoc J.


Introduction: Over time, the incidence of nephrolithiasis has risen significantly, and patient populations have become increasingly complex. Our study aimed to determine the impact of changes in patient demographics on percutaneous nephrolithotomy (PCNL) outcomes.

Methods: A retrospective analysis of a prospectively collected database was carried out from 1990-2015. Patient demographics, comorbidities, stone and procedure characteristics were analyzed. Multivariate logistic regression was used to evaluate differences in operative duration, complications, stone-free rate, and length of stay.

Results: A total of 2486 patients with a mean age of 54±15 years, body mass index (BMI) of 31±8, and stone surface area of 895±602 mm2 were analyzed; 47% of patients had comorbidities, including hypertension (22%), diabetes mellitus (14%), and cardiac disease (13%). Complication rate was 19%, including a 2% rate of major complications (Clavien grade III-V). There was a statistically significant increase in patient age, BMI, and comorbidities over time, which was correlated with an increased complication rate (odds ratio [OR] 1.15; p=0.010). The overall transfusion rate was 1.0% and remained stable (p=0.131). With time, both OR duration (mean Δ 16 minutes; p<0.001) and hospital length of stay (mean Δ 2.4 days; p<0.001) decreased significantly. Stone-free rate of 1873 patients with available three-month followup was 87% and decreased significantly over time (OR 1.09; p<0.001), but was correlated with an increased use of computed tomography (CT) scans for followup imaging.

Conclusions: Despite an increasingly complex patient population, PCNL remains a safe and effective procedure with a high stone-free rate and low risk of complications.

Conflict of interest statement

Competing interests: Dr. Violette has been a speakers’ bureau member for Janssen and Sanofi (no honoraria). Dr. Tailly has received honoraria from Cook Medical and Storz. Dr. Denstedt holds a patent for a product marketed by Cook Medical. Dr. Razvi receives royalties for a product marketed by Cook Medical; and receives endourology fellowship support from Cook Medical and Storz Medical. The remaining authors report no competing personal or financial interests related to this work

Similar articles

See all similar articles

LinkOut - more resources